Imipenem/cilastatin

DRUG10 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Pfizer, Ruijin Hospital, Merck Sharp & Dohme LLC, Shionogi

Conditions

APAbdominal AbscessAcinetobacter Baumannii InfectionAcute PyelonephritisBacterial InfectionsComplicated Urinary Tract InfectionIntra-abdominal InfectionIntra-abdominal Infections

Phase 1

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

CompletedNCT02971423

Entasis TherapeuticsAcinetobacter Baumannii Infection

Start: 2016-10-31End: 2017-06-01Updated: 2017-06-05

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

CompletedNCT04801043

Evopoint Biosciences Inc.Bacterial Infections

Start: 2021-03-02End: 2022-01-31Updated: 2023-02-16

Phase 2

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

CompletedNCT00515034

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Abdominal Abscess, Bacterial Infections, Pneumonia +2

Start: 2007-10-31End: 2008-11-30Updated: 2019-03-19

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

CompletedNCT00690378

PfizerComplicated Urinary Tract Infection

Start: 2008-11-30End: 2010-07-31Updated: 2018-05-25

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

TerminatedNCT00707239

PfizerPneumonia, Bacterial

Start: 2008-12-31End: 2011-06-30Updated: 2012-07-10

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

CompletedNCT01506271

Merck Sharp & Dohme LLCIntra-abdominal Infections

Start: 2012-06-01End: 2014-08-12Updated: 2019-06-10

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

CompletedNCT02321800

ShionogiUrinary Tract Infections

Start: 2015-02-05End: 2016-08-16Updated: 2019-12-12

Phase 3

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

CompletedNCT05887908

Meiji Seika Pharma Co., Ltd.Acute Pyelonephritis, AP, Complicated Urinary Tract Infection +1

Start: 2023-05-23End: 2024-11-26Updated: 2025-12-24

Phase 4

Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

Ruijin HospitalMethicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated

Start: 2011-06-30Target: 60Updated: 2011-05-19

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

CompletedNCT01721408

PfizerIntra-abdominal Infection

Start: 2012-11-30End: 2015-10-31Updated: 2018-04-09

Related Papers

Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.

2022-02-2013 citations

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation

Therapeutic Advances in Infectious Disease2021-01-014 citations

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)

Clinical Infectious Diseases2020-12-0147 citations

1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections

Open Forum Infectious Diseases2020-10-015 citations

Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.

2020-08-0115 citations

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.

2020-06-2324 citations

1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study

Open Forum Infectious Diseases2019-10-01

666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study

Open Forum Infectious Diseases2019-10-01

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China

Therapeutics and Clinical Risk Management2018-11-0112 citations

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

2018-10-25294 citations

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Antimicrobial Agents and Chemotherapy2016-08-09177 citations

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Clinical Infectious Diseases2016-06-16338 citations

Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.

2013-01-28173 citations

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.

2012-11-21180 citations